{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:21:20Z","timestamp":1787023280208,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Octreotide LAR is used in patients for control of carcinoid syndrome (CS) and other symptoms of hormone hypersecretion. The aim of this study was to examine reasons for octreotide LAR dose escalation and observe CS symptom improvement in patients with neuroendocrine tumors (NETs) who underwent octreotide LAR dose escalation at three cancer referral centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Medical records for patients with diagnosis of carcinoid or pancreatic NET who had received one dose or more of octreotide LAR above 30 mg every 4 weeks from 2000 to 2012 were reviewed. Reasons for dose escalation and symptomatic outcomes were abstracted for each patient 3 months prior to and up to 12 months following the dose escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Of the evaluated 239 NET patients, 53% were male, mean age at first dose escalation was 60 years (standard deviation [SD]: 11 years), and mean time from octreotide LAR initiation to first dose escalation was 1.7 years (SD: 2.0 years). The primary reasons reported for dose escalation were carcinoid or hormonal syndrome (62%) or radiographic progression (28%). The most common dose changes at the first dose escalation were 40 mg every 4 weeks (71%) and 60 mg every 4 weeks (18%). Of 90 patients in whom flushing was reported prior to first dose escalation, 73 (81%) were reported to have experienced improvement or resolution of their symptoms following the dose escalation. Of 107 patients who were reported to have experienced diarrhea before the first dose escalation, 85 (79%) were reported to have experienced improvement or resolution after first dose escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>The goal of improved symptom control is a common reason for dose escalation of octreotide LAR. This study suggests that escalation to above the standard dose of octreotide LAR of 30 mg every 4 weeks may result in improved CS symptom control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0120","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T01:47:48Z","timestamp":1407289668000},"page":"930-936","source":"Crossref","is-referenced-by-count":97,"title":["Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study"],"prefix":"10.1093","volume":"19","author":[{"given":"Jonathan R.","family":"Strosberg","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al B.","family":"Benson","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Goldman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of South Florida, Tampa, Florida, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred W.","family":"Rademaker","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Kulke","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"key":"2021122309081915500_B1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309081915500_B2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1590\/S0004-27302005000500028","article-title":"Carcinoid syndrome: Diagnosis and medical management","volume":"49","author":"Van der Lely","year":"2005","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2021122309081915500_B3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/MPA.0b013e31821f66b4","article-title":"Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period","volume":"40","author":"Anthony","year":"2011","journal-title":"Pancreas"},{"key":"2021122309081915500_B4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s002689900020","article-title":"Carcinoid tumors: Development of our knowledge","volume":"20","author":"Creutzfeldt","year":"1996","journal-title":"World J Surg"},{"key":"2021122309081915500_B5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jso.20179","article-title":"Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract","volume":"89","author":"Rorstad","year":"2005","journal-title":"J Surg Oncol"},{"key":"2021122309081915500_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP13262.RA","article-title":"Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Current approaches and future options","volume":"20","author":"Strosberg","year":"2014","journal-title":"Endocr Pract"},{"key":"2021122309081915500_B7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2012.02.010","article-title":"Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective","volume":"39","author":"Phan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2021122309081915500_B8","article-title":"A randomized, double-blind, placebo-controlled study of lanreotide antiproliferative response in patients with gastroenteropancreatic neuroendocrine tumors (CLARINET)","volume-title":"Presented at: European Cancer Congress","author":"Caplin","year":"2013"},{"key":"2021122309081915500_B9","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309081915500_B10","volume-title":"Sandostatin LAR depot [prescribing information]","year":"1988"},{"issue":"suppl","key":"2021122309081915500_B11","doi-asserted-by":"crossref","first-page":"4274a","DOI":"10.1200\/jco.2004.22.90140.4274","article-title":"Octreotide LAR doses used in clinical practice: Results from an internet survey and a clinical practice","volume":"22","author":"Anthony","year":"2004","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122309081915500_B12","doi-asserted-by":"crossref","first-page":"e14550a","DOI":"10.1200\/jco.2012.30.15_suppl.e14550","article-title":"Dosing patterns of octreotide LAR among elderly patients with neuroendocrine tumors: Analysis of the SEER-Medicare database","volume":"30","author":"Xu","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309081915500_B13","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.4142","article-title":"Dosing patterns for octreotide LAR in neuroendocrine tumor (NET) patients: NCCN NET outcomes database","volume-title":"Presented at: American Society of Clinical Oncology annual meeting","author":"Strosberg","year":"2013"},{"key":"2021122309081915500_B14","first-page":"4127","article-title":"High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors","volume":"29","author":"Chadha","year":"2009","journal-title":"Anticancer Res"},{"key":"2021122309081915500_B15","first-page":"326","article-title":"Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses","volume":"35","author":"Ferolla","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"2021122309081915500_B16","first-page":"81","article-title":"Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors","volume":"6","author":"Strosberg","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"2021122309081915500_B17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"2021122309081915500_B18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.6004\/jnccn.2012.0075","article-title":"Neuroendocrine tumors","volume":"10","author":"Kulke","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122309081915500_B19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122309081915500_B20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MPA.0b013e31826d3a17","article-title":"Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: Consensus results from a modified Delphi process","volume":"42","author":"Strosberg","year":"2013","journal-title":"Pancreas"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2014-0120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/9\/930\/41862423\/oncolo_19_9_930.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/9\/930\/41862423\/oncolo_19_9_930.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T21:04:33Z","timestamp":1640293473000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/9\/930\/6399562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,8,5]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0120","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,9,1]]},"published":{"date-parts":[[2014,8,5]]}}}